Table 3 Conditions shown to respond to omalizumab/anti-IgE* therapy

Allergic rhinitis

[66,69,85-89]

Allergic asthma:

   • Moderate-severe persistent disease

[55,64,90-94]

   • Steroid-sparing effect

[57,95,96]

Churg-Strauss syndrome

[97,98]

Peanut anaphylaxis*

[52,70,71,99,100]

Uticaria

[78]

Angioedema

[101]

Immunotherapy reactions

[102]

Rubber latex allergy

[79]